Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Bukowski

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
The Biochemical Journal|December 8, 1998
Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalphaM Aoyama, D R Grabowski, G R Dubyak, et al.
Blood|October 9, 1998
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cellsM Aoyama, D R Grabowski, R J Isaacs, et al.
The Cancer Journal From Scientific American|February 24, 2000
Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escapeP Rayman, R G Uzzo, V Kolenko, et al.
Cancer Research|March 15, 1993
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptorsJ P Alexander, S Kudoh, K A Melsop, et al.
Cancer Treatment Reports|July 1, 1983
Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group StudyF R Ahmann, F L Meyskens, S E Jones, et al.
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Cancer Research|February 1, 1991
Phase I trial of natural human interferon beta in metastatic malignancyR M Bukowski, J S Sergi, W J Sharfman, et al.
The Journal of Clinical Investigation|September 24, 1999
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cellsR G Uzzo, P Rayman, V Kolenko, et al.
American Journal of Clinical Oncology|February 1, 1994
Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapyD J Adelstein, T W Rice, G A Boyce, et al.
Cancer Treatment Reports|December 1, 1987
Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group StudyN Oishi, J Berenberg, B A Blumenstein, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
The Biochemical Journal|December 8, 1998
Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalphaM Aoyama, D R Grabowski, G R Dubyak, et al.
Blood|October 9, 1998
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cellsM Aoyama, D R Grabowski, R J Isaacs, et al.
The Cancer Journal From Scientific American|February 24, 2000
Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escapeP Rayman, R G Uzzo, V Kolenko, et al.
Cancer Research|March 15, 1993
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptorsJ P Alexander, S Kudoh, K A Melsop, et al.
Cancer Treatment Reports|July 1, 1983
Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group StudyF R Ahmann, F L Meyskens, S E Jones, et al.
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Cancer Research|February 1, 1991
Phase I trial of natural human interferon beta in metastatic malignancyR M Bukowski, J S Sergi, W J Sharfman, et al.
The Journal of Clinical Investigation|September 24, 1999
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cellsR G Uzzo, P Rayman, V Kolenko, et al.
American Journal of Clinical Oncology|February 1, 1994
Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapyD J Adelstein, T W Rice, G A Boyce, et al.
Cancer Treatment Reports|December 1, 1987
Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group StudyN Oishi, J Berenberg, B A Blumenstein, et al.
Pageof 17